Bottom line
A four-component research-peptide combination (GHK-Cu + KPV + BPC-157 + TB-500) representing the GLOW formulation plus KPV, a tripeptide anti-inflammatory fragment of alpha-MSH. The name is a vendor-coined acronym. No published study tests this specific four-component combination.
No established or recommended human dose. Composition (especially GHK-Cu loading) varies markedly by vendor.
Name and formulation variability
| Variant label | Market observation (source/date) | Claimed components and amounts | Verification limits |
|---|---|---|---|
| KLOW | 2026 listing — AminoCore Research | GHK-Cu, KPV, BPC-157, TB-500; 50 / 10 / 10 / 10 mg (80 mg total) | Seller-declared |
| KLOW | 2026 listing — Durham Peptides | GHK-Cu, KPV, BPC-157, TB-500; 50 / 10 / 10 / 10 mg | Seller-declared; unverified |
| KLOW | 2026 listing — BergdorfBio | GHK-Cu, KPV, BPC-157, TB-500; 25 / 10 / 10 / 10 mg (55 mg total) | Seller-declared |
| KLOW70 | Observed variant label | GHK-Cu, KPV, BPC-157; 50 / 10 / 10 mg; TB-500 not listed | Seller-declared |
The KLOW name is not standardised; it is a marketing acronym (KPV, Lysyl=GHK-Cu, Overall repair=BPC, Wound=TB-500). GHK-Cu loading ranges 25–50 mg; some variants omit TB-500.
Observed four-component KLOW listings name GHK-Cu, KPV, BPC-157, and TB-500. The observed KLOW70 variant names GHK-Cu, KPV, and BPC-157 but does not list TB-500. Each component has separate evidence; no multi-component study or co-stability study was identified.
Component evidence
| Component | Separate evidence | Combination evidence | Compatibility |
|---|---|---|---|
| GHK-Cu | An entry with substantial scientific visibility or identity value. Biological rationale and non-human evidence do not establish patient benefit. 定義の出典: Scope and selection methodology · 用語集 tripeptide; separate matrix-biology and antioxidant domains | Not identified on this page | No published multi-peptide co-Freeze-drying: water is removed by sublimation under reduced pressure, which can improve the stability of peptides and yield a porous dry matrix. Water removal does not sterilize a product, prove its quality, or define how it should later be handled. 定義の出典: Lyophilization, formulation, and stability primer · 用語集 stability study |
| KPV | Lys-Pro-Val, a C-terminal alpha-MSH fragment; separate Evidence from in vitro or animal studies with no adequate human efficacy evidence — the atlas Grade D lane. 定義の出典: Evidence grading methodology · 用語集 inflammation and transport findings | Not identified on this page | Interaction with other components unstudied |
| BPC-157 | Separate preclinical VEGFR2/NO, GI, and tendon-model domains | Not identified on this page | Not identified on this page |
| TB-500 | Identity ambiguity first: full-length thymosin beta-4 versus a short fragment; separate actin and cell-migration domains | Not identified on this page | Identity ambiguity prevents exact compatibility assessment |
Combination-specific studies
No published peer-reviewed study tests the GHK-Cu + KPV + BPC-157 + TB-500 four-component combination. The rationale is mechanistic complementarity: four non-overlapping pathways (ECM remodelling, anti-inflammation, angiogenesis, cell migration).
Safety and interaction uncertainties
Four-peptide combination maximises uncertainty: more components = more potential interactions
KPV's NF-κB mechanism may theoretically interfere with the inflammatory phase of repair
Fixed ratio prevents independent dose modulation
No published stability data for the co-Freeze-drying: water is removed by sublimation under reduced pressure, which can improve the stability of peptides and yield a porous dry matrix. Water removal does not sterilize a product, prove its quality, or define how it should later be handled. 定義の出典: Lyophilization, formulation, and stability primer · 用語集 four-peptide mixture
Molar ratios are massively skewed: tripeptides (GHK-Cu, KPV) dominate by >93% of molar content
Regulatory and product-quality notes
None of the four components is FDA-approved
All are "research use only" products
KPV is sometimes included in cosmetic products as a "peptide complex"
The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. 定義の出典: WADA and sport regulation brief · 用語集 status varies by component; BPC-157 and TB-500 are prohibited
Evidence gaps
No combination-specific study of any kind
No stability or compatibility data for the four-peptide mixture
No dose-ratio optimisation
No human data for any component for the claimed mechanisms
The explicit evidence-gap rail is unchanged by the number of listed components: no study or co-stability evidence for the market mixture was identified. Compare GLOW, Wolverine, and the narrower BPC-157 + KPV pairing.
Sources
AminoCore Research. KLOW Blend Analysis. https://aminocoreresearch.com/articles/klow-blend-bpc-157-tb-500-ghk-cu-kpv accessed 2026-08-06.
Durham Peptides. Inside the KLOW Blend. https://www.durhampeptides.ca/post/inside-klow-blend-four-component-breakdown accessed 2026-08-06.
BergdorfBio. KLOW Stack Guide. https://bergdorfbio.com/en/us/guides/klow-stack-leitfaden accessed 2026-08-06.
Your Peptide Brand. KLOW Blend Research Guide. https://yourpeptidebrand.com/klow-blend-research-guide/ accessed 2026-08-06.
Dalmasso G, et al. Am J Physiol Gastrointest Liver Physiol. 2008;295(1):G43-G54. PMID 18436621.